EP Patent

EP0376518B1 — Phospholipid nucleosides

Assigned to Eli Lilly and Co · Expires 1995-11-29 · 30y expired

What this patent protects

Patent listed against Skyclarys.

Drugs covered by this patent

Skyclarys (OMAVELOXOLONE) · Biogen Us

Patent Metadata

Patent number: EP0376518B1
Jurisdiction: EP
Classification: —
Expires: 1995-11-29
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.